Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Inmune Bio ( (INMB) ) is now available.
On July 24, 2025, INmune Bio Inc. announced that additional analyses from its Phase 2 MINDFuL trial of XPro™, a novel TNF inhibitor, will be presented at the Alzheimer’s Association International Conference in Toronto. While the primary endpoint was not met, the trial showed promising results in a subpopulation of patients with specific biomarkers, suggesting potential benefits in slowing cognitive decline in early-stage Alzheimer’s disease. The company is seeking a strategic partnership to further develop XPro™.
The most recent analyst rating on (INMB) stock is a Buy with a $22.00 price target. To see the full list of analyst forecasts on Inmune Bio stock, see the INMB Stock Forecast page.
Spark’s Take on INMB Stock
According to Spark, TipRanks’ AI Analyst, INMB is a Neutral.
Inmune Bio’s overall stock score is hindered by significant financial challenges, including declining revenue and ongoing losses. While technical analysis shows mixed signals, valuation metrics suggest overvaluation. Positive corporate events and earnings call highlights provide some optimism, but financial instability and operational challenges remain key risks.
To see Spark’s full report on INMB stock, click here.
More about Inmune Bio
INmune Bio Inc. is a publicly traded, clinical-stage biotechnology company focused on developing treatments targeting the innate immune system to combat diseases. The company has three product platforms, including the Dominant-Negative Tumor Necrosis Factor (DN-TNF) platform, which is in clinical trials for conditions such as Mild Alzheimer’s disease and treatment-resistant depression. Other platforms include the Natural Killer Cell Priming Platform and CORDStrom™, aimed at cancer and chronic inflammation-related diseases.
Average Trading Volume: 2,731,379
Technical Sentiment Signal: Sell
Current Market Cap: $73.91M
For detailed information about INMB stock, go to TipRanks’ Stock Analysis page.